Compare KPTI & PGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KPTI | PGP |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.6M | 102.9M |
| IPO Year | 2013 | N/A |
| Metric | KPTI | PGP |
|---|---|---|
| Price | $5.57 | $8.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $14.67 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 46.9K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.84% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $3.51 | $6.56 |
| 52 Week High | $10.99 | $9.41 |
| Indicator | KPTI | PGP |
|---|---|---|
| Relative Strength Index (RSI) | 32.41 | 38.98 |
| Support Level | $3.93 | $8.03 |
| Resistance Level | $6.82 | $8.37 |
| Average True Range (ATR) | 0.83 | 0.21 |
| MACD | -0.31 | -0.01 |
| Stochastic Oscillator | 13.24 | 40.44 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.